# A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Study · id `cardio:ct-nct06603571` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06603571](<https://clinicaltrials.gov/study/NCT06603571>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06603571

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 367 participants.

## Technical summary

Registry record NCT06603571. Randomized; double masking; primary purpose treatment. Start 2024-09-20 (actual); primary completion 2026-07-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 367 participants (enrolled count; ClinicalTrials.gov record NCT06603571, source copy `cardio:ctgov-nct06603571-2026-09-29`, retrieved 2026-10-26)
- Started: 2024-09-20 (actual) (ClinicalTrials.gov record NCT06603571, source copy `cardio:ctgov-nct06603571-2026-09-29`, retrieved 2026-10-26)
- Primary completion: 2026-07-01 (actual) (ClinicalTrials.gov record NCT06603571, source copy `cardio:ctgov-nct06603571-2026-09-29`, retrieved 2026-10-26)
- Completion: 2026-09-14 (actual) (ClinicalTrials.gov record NCT06603571, source copy `cardio:ctgov-nct06603571-2026-09-29`, retrieved 2026-10-26)
- Countries: United States; Argentina (ClinicalTrials.gov record NCT06603571, source copy `cardio:ctgov-nct06603571-2026-09-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06603571-2026-09-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Condition: Obesity
- Condition: Overweight
- Intervention (Drug): LY3841136
- Intervention (Drug): Tirzepatide
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: b683f3afa363d099e5ed7e2994c13740a829556c79903404da305c84246ec39c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
